Onalespib Drug Asset Due Diligence Report 2026

This Onalespib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Onalespib can convert its Small molecule drug profile and HSP90 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Onalespib (query alias: Onalespib)
Modality / target	Small molecule drug; HSP90; HSP90 inhibitors
Highest global status	Phase 2
Originator	Astex Pharmaceuticals, Inc.
Active developers	University of Uppsala, Otsuka Holdings Co., Ltd.

The MCP disease footprint includes Non-Small Cell Lung Cancer, Colorectal Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT02898207	Phase 1	Completed	28	Primary endpoint not disclosed in English source
NCT02627430	Phase 1	Withdrawn	0	Primary endpoint not disclosed in English source
NCT02572453	Phase 2	Terminated	25	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Phase I Study of AT13387 in Combination With Dabrafenib and Trametinib in Patients With BRAF-Mutant Melanoma and Other Solid Tumors

Phase 1; n=22; evaluation: Not stated in English source. Reported fields: Maximum Tolerated Dose of Dabrafenib = 150 mg ; Toxicity = 0 dose limiting toxicities

Dose‐escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF‐mutant solid tumors

Phase 1; n=22; evaluation: Not stated in English source. Reported fields: DCR = 47.6 % ( 29% - 67%)

Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors.

Phase 1; n=22; evaluation: Not stated in English source. Reported fields: DCR = 47.6 % (90%CI, 29% - 67%)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Onalespib addresses Non-Small Cell Lung Cancer, Colorectal Cancer. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 9 matched transaction record(s) under the scope “target-level comparable: HSP90.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: HSP90 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2023-09-25	MC2 Therapeutics Acquires Option to Phase 2 Oral Drug Candidate for Hidradenitis Suppurativa and Other Indications	Phase 1	Financial terms not disclosed
2020-07-27	AxoProtego Therapeutics has licensed a novel investigational therapy for chemotherapy-induced peripheral neuropathy (CIPN) from The Johns Hopkins University.	Not disclosed	Financial terms not disclosed
2020-03-19	Tarveda Therapeutics and SciClone Pharmaceuticals International Establish Licensing Agreement for PEN-866 in Greater China	Phase 2	US$4.0M upfront; US$75.0M milestones; US$79.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “HSP90 inhibitors for the treatment of cancer”. The milestone feed surfaced a patent-application signal described as “Methods of modulating ATXN2 expression”. The milestone feed surfaced a patent-application signal described as “Application of Onalspib in preparation of medicine for preventing and/or treating adenovirus infection”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO